<DOC>
	<DOC>NCT02411929</DOC>
	<brief_summary>This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of 14^C-labeled ertugliflozin in healthy male participants.</brief_summary>
	<brief_title>A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Healthy male subjects between the ages of 18 and 65 years. Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight &gt;50 kg (110 lbs.) Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies). Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection). A positive urine drug screen for drugs of abuse or recreational drugs. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results. History of abuse of alcohol or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Current smokers and those who have smoked any substance within the last 12 months. Treatment with an investigational drug within 1 month preceding the first dose of study medication. Have participated in any clinical study with exposure to 14^C in the last 12 months. Any radiation exposure, including that which is projected to result from the present study, excluding background radiation but including diagnostic xrays and other medical exposures. No occupationally exposed worker, as defined in the Ionising Radiation Regulation 1999, shall participate in the study. Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days prior to the first dose of study medication. Use of herbal supplements within 28 days prior to the first dose of study medication. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing. Participants who have previously participated in a clinical trial for ertugliflozin. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>